Greg Jefferys pass along a Freedom of Information Request made to the FDA relating to reported side effects (adverse drug reactions for Harvoni).
Here it is in the form delivered:
Harvoni(2275)-DetailedReport.pdf
Which is a bit hard to get your head round, but here is what happens if you run it through a bit of software to calculate the frequency of the reports (anything that was reported < 3 times has been ignored.
20.8% (158/759) Headache
18.1% (137/759) Fatigue
5.9% (45/759) Insomnia
5.7% (43/759) Nausea
5.7% (43/759) Diarrhoea
3.7% (28/759) Rash
3.2% (24/759) Anxiety
2.8% (21/759) Vomiting
2.0% (15/759) Nasopharyngitis
2.0% (15/759) Pain
1.8% (14/759) Dyspnoea
1.8% (14/759) Dizziness
1.8% (14/759) Dyspepsia
1.7% (13/759) Abdominal pain
1.7% (13/759) Hypertension
1.7% (13/759) Blood pressure increased
1.7% (13/759) Pruritus
1.4% (11/759) Pyrexia
1.4% (11/759) Depression
1.4% (11/759) Myalgia
1.4% (11/759) Feeling abnormal
1.4% (11/759) Peripheral swelling
1.4% (11/759) Chest pain
1.4% (11/759) Abdominal pain upper
1.3% (10/759) Tinnitus
1.3% (10/759) Influenza
1.3% (10/759) Hepatitis
1.2% (9/759) Cough
1.2% (9/759) Malaise
1.2% (9/759) Arthralgia
1.2% (9/759) Back pain
1.2% (9/759) Weight decreased
1.2% (9/759) Chills
1.2% (9/759) Abdominal discomfort
1.2% (9/759) Confusional state
1.2% (9/759) Pain in extremity
1.2% (9/759) Overdose
1.1% (8/759) Muscle spasms
1.1% (8/759) Constipation
1.1% (8/759) Drug dose omission
1.1% (8/759) Irritability
1.1% (8/759) Influenza like illness
1.1% (8/759) Accidental overdose
1.1% (8/759) Encephalopathy
1.1% (8/759) Somnolence
1.1% (8/759) Rash generalised
0.9% (7/759) Asthenia
0.9% (7/759) Alopecia
0.9% (7/759) Sleep disorder
0.9% (7/759) Drug interaction
0.9% (7/759) Aspartate aminotransferase increased
0.9% (7/759) Decreased appetite
0.8% (6/759) Gastrooesophageal reflux disease
0.8% (6/759) Alanine aminotransferase increased
0.8% (6/759) Death
0.8% (6/759) Convulsion
0.8% (6/759) Sinusitis
0.8% (6/759) Migraine
0.8% (6/759) Ascites
0.8% (6/759) Drug ineffective
0.8% (6/759) Agitation
0.7% (5/759) Flatulence
0.7% (5/759) Pneumonia
0.7% (5/759) Blood bilirubin increased
0.7% (5/759) Dysphagia
0.7% (5/759) Haemoglobin decreased
0.7% (5/759) Rash erythematous
0.7% (5/759) Chest discomfort
0.7% (5/759) Oropharyngeal pain
0.7% (5/759) Abdominal distension
0.7% (5/759) Vision blurred
0.7% (5/759) Blood glucose increased
0.7% (5/759) Visual impairment
0.7% (5/759) Blood creatinine increased
0.5% (4/759) Hyperhidrosis
0.5% (4/759) Abnormal dreams
0.5% (4/759) Cardiac failure congestive
0.5% (4/759) Sepsis
0.5% (4/759) Unknown
0.5% (4/759) Syncope
0.5% (4/759) Nightmare
0.5% (4/759) Lower respiratory tract infection
0.5% (4/759) Lymphadenopathy
0.5% (4/759) Condition aggravated
0.5% (4/759) Stomatitis
0.5% (4/759) Palpitations
0.5% (4/759) Hot flush
0.5% (4/759) Renal impairment
0.5% (4/759) Fluid retention
0.5% (4/759) Pruritus generalised
0.4% (3/759) Renal failure acute
0.4% (3/759) Local swelling
0.4% (3/759) Blood phosphorus decreased
0.4% (3/759) Hypoglycaemia
0.4% (3/759) Retching
0.4% (3/759) Balance disorder
0.4% (3/759) Chromaturia
0.4% (3/759) Memory impairment
0.4% (3/759) Hepatic failure
0.4% (3/759) Product
0.4% (3/759) Bronchitis
0.4% (3/759) Rash pruritic
0.4% (3/759) Blood alkaline phosphatase increased
0.4% (3/759) Dermatitis bullous
0.4% (3/759) Anaemia
0.4% (3/759) Epistaxis
0.4% (3/759) Blood potassium decreased
0.4% (3/759) Epilepsy
0.4% (3/759) Toxicity to various agents
0.4% (3/759) Vertigo
0.4% (3/759) Dehydration
0.4% (3/759) Cerebral haemorrhage
0.4% (3/759) Asterixis
0.4% (3/759) Psychomotor hyperactivity
0.4% (3/759) Blood pressure fluctuation
0.4% (3/759) Urticaria
0.4% (3/759) Feeling cold
0.4% (3/759) Cardiac arrest
0.4% (3/759) Upper respiratory tract infection
0.4% (3/759) Unevaluable event
0.4% (3/759) Disorientation
0.4% (3/759) Speech disorder
0.4% (3/759) Diazepam
0.4% (3/759) Cognitive disorder
0.4% (3/759) Nephrotic syndrome
0.4% (3/759) Hepatic cirrhosis
.
